Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALPG | P10696 | 3/20 | 0.38 |
| ▸ | CDC25A | P30304 | 2/20 | 0.38 |
| ▸ | CDC25B | P30305 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 4/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 3/20 | 0.37 |
| ▸ | KLK7 | P49862 | 1/20 | 0.37 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.37 |
| ▸ | TUBB | P07437 | 1/20 | 0.37 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | XDH | P47989 | 1/20 | 0.37 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.37 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.37 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.37 |
| ▸ | TUBB3 | Q13509 | 1/20 | 0.37 |
| ▸ | TUBB2A | Q13885 | 1/20 | 0.37 |
| ▸ | TUBB8 | Q3ZCM7 | 1/20 | 0.37 |
| ▸ | TUBA3E | Q6PEY2 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL930671 | 0.79 | MAPT (0.46) | MAPTLMNAPKMESR1MEN1 | |
| SCHEMBL1304760 | 0.79 | RAB9A (0.35) | MAPTLMNARAB9ANPC1MEN1 | |
| SCHEMBL10012186 | 0.72 | OXTR (0.61) | RAB9AALDH1A1MEN1KMT2AHTT | |
| SCHEMBL6406225 | 0.72 | OXTR (0.55) | ALPGCDC25ACDC25BMAPTRAB9A | |
| SCHEMBL3700889 | 0.71 | HPGD (0.44) | MAPTLMNARAB9APKMNPC1 | |
| SCHEMBL931243 | 0.71 | OXTR (0.61) | MAPTLMNAALDH1A1MEN1KMT2A | |
| SCHEMBL930860 | 0.70 | GAA (0.42) | MAPTLMNAABCB1ESR1ALDH1A1 | |
| SCHEMBL14342301 | 0.70 | RAB9A (0.38) | MAPTLMNARAB9AKLK7TUBB4A | |
| SCHEMBL2551450 | 0.69 | OXTR (0.56) | MAPTLMNAATMNPC1ALDH1A1 | |
| SCHEMBL14925080 | 0.69 | HSP90AA1 (0.41) | MAPTATMALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2035396-A2 | TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | Synta Pharmaceuticals Corporation (US) | 2009-03-18 | — | — | EP | claimed |
| WO-2007139967-A2 | TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | SYNTA PHARMACEUTICALS CORP. (US) | 2007-12-06 | — | — | WO | claimed |
| US-9206162-B2 | Triazole compounds that modulate Hsp90 activity | SYNTA PHARMACEUTICALS CORP. (US) | 2015-12-08 | — | — | US | disclosed |
| US-9206162-B2 | Triazole compounds that modulate Hsp90 activity | SYNTA PHARMACEUTICALS CORP. (US) | 2015-12-08 | — | — | US | disclosed |
| US-9206162-B2 | Triazole compounds that modulate Hsp90 activity | SYNTA PHARMACEUTICALS CORP. (US) | 2015-12-08 | — | — | US | disclosed |
| US-20150266858-A1 | TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | LSI FINANCING LLC, AS ADMINISTRATIVE AGENT | 2015-09-24 | — | — | US | disclosed |
| US-20150266858-A1 | TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | LSI FINANCING LLC, AS ADMINISTRATIVE AGENT | 2015-09-24 | — | — | US | disclosed |
| US-20150266858-A1 | TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | LSI FINANCING LLC, AS ADMINISTRATIVE AGENT | 2015-09-24 | — | — | US | disclosed |
| US-9006277-B2 | Triazole compounds that modulate HSP90 activity | SYNTA PHARMACEUTICALS CORP. (US) | 2015-04-14 | — | — | US | disclosed |
| US-9006277-B2 | Triazole compounds that modulate HSP90 activity | SYNTA PHARMACEUTICALS CORP. (US) | 2015-04-14 | — | — | US | disclosed |
| US-9006277-B2 | Triazole compounds that modulate HSP90 activity | SYNTA PHARMACEUTICALS CORP. (US) | 2015-04-14 | — | — | US | disclosed |
| US-20110319447-A1 | TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | SYNTA PHARMACEUTICALS CORP. (US) | 2011-12-29 | — | — | US | disclosed |
| US-8053456-B2 | Triazole compounds that modulate Hsp90 activity | SYNTA PHARMACEUTICALS CORP. (US) | 2011-11-08 | — | — | US | disclosed |
| US-8053456-B2 | Triazole compounds that modulate Hsp90 activity | SYNTA PHARMACEUTICALS CORP. (US) | 2011-11-08 | — | — | US | disclosed |
| US-8053456-B2 | Triazole compounds that modulate Hsp90 activity | SYNTA PHARMACEUTICALS CORP. (US) | 2011-11-08 | — | — | US | disclosed |
| EP-2035396-A2 | TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | Synta Pharmaceuticals Corporation (US) | 2009-03-18 | — | — | EP | disclosed |
| US-20080176840-A1 | e.g. 4-(4-(6-(N-(2-methoxyethyl)-N-methylamino)pyridin-3-yl)-5-hydroxy-4H-1,2,4-triazol-3-yl)-6-isopropylbenzene-1,3-diol; Heat Shock Protein 90 (HSP90) modulator; antiproliferative, anticarcinogenic, antiinflammatory agent; angiogenesis inhibition, infections | SYNTA PHARMACEUTICALS CORP | 2008-07-24 | — | — | US | disclosed |
| US-20080176840-A1 | e.g. 4-(4-(6-(N-(2-methoxyethyl)-N-methylamino)pyridin-3-yl)-5-hydroxy-4H-1,2,4-triazol-3-yl)-6-isopropylbenzene-1,3-diol; Heat Shock Protein 90 (HSP90) modulator; antiproliferative, anticarcinogenic, antiinflammatory agent; angiogenesis inhibition, infections | SYNTA PHARMACEUTICALS CORP | 2008-07-24 | — | — | US | disclosed |
| US-20080176840-A1 | e.g. 4-(4-(6-(N-(2-methoxyethyl)-N-methylamino)pyridin-3-yl)-5-hydroxy-4H-1,2,4-triazol-3-yl)-6-isopropylbenzene-1,3-diol; Heat Shock Protein 90 (HSP90) modulator; antiproliferative, anticarcinogenic, antiinflammatory agent; angiogenesis inhibition, infections | SYNTA PHARMACEUTICALS CORP | 2008-07-24 | — | — | US | disclosed |
| WO-2007139967-A2 | TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | SYNTA PHARMACEUTICALS CORP. (US) | 2007-12-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080176840-A1 | e.g. 4-(4-(6-(N-(2-methoxyethyl)-N-methylamino)pyridin-3-yl)-5-hydroxy-4H-1,2,4-triazol-3-yl)-6-isopropylbenzene-1,3-diol; Heat Shock Protein 90 (HSP90) modulator; antiproliferative, anticarcinogenic, antiinflammatory agent; angiogenesis inhibition, infections | HSP90AB1, HSP90AB2P, HSP90B1 | ALPG 3473/4885CDC25A 214/4885CDC25B 133/4885 |
| US-20110319447-A1 | TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | HSP90AB1, HSP90B1, HSP90AA1 | ALPG 4187/4885CDC25A 193/4885CDC25B 240/4885 |
| US-20150266858-A1 | TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | HSP90AB1, HSP90B1, HSP90AA1 | ALPG 4187/4885CDC25A 193/4885CDC25B 240/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.